marked.bio

VEGFR TKI · small molecule

axitinib

2 active trials across 5 of our biomarkers, targeting VEGFR1-3. Not approved for any biomarker on marked.bio yet.

Also known as AG-013736, Inlyta.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
ALK fusion 1 1 Phase 2
MSI-H / dMMR 1 2 Phase 2
BRAF V600E 0 1 –
BRCA1/2 mutation 0 1 –
MET exon 14 skipping 0 1 –

Trials

2 of 6 trials shown

  1. MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas

    Not yet recruiting Phase 2 Fudan University Started 2026Primary completion 2027-12 NCT07816770

    toripalimabaxitinib

    …e-deficient renal cell carcinoma, succinate dehydrogenase-deficient renal cell carcinoma, ALK-rearranged renal cell carcinoma, and renal cell carcinoma not otherwise specified or unclassified af…

    ALK fusionMetastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary Carcinomas

  2. Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

    Active, not recruiting Phase 2 Dana-Farber Cancer Institute Started 2016Primary completion 2023-11 NCT02912572

    avelumabtalazoparibaxitinib

    MSI-H as determined by immunohistochemical complete loss of expression (absence of nuclear immu…

    MSI-H / dMMRMetastatic Endometrial Cancer